Prostate cancer initiation, progression, and metastasis to bone with ...

Prostate cancer initiation , progression , and metastasis to bone with upregulation and downregulation of tumor suppressor and proto-oncogenes involved in various signaling pathways.

Prostate cancer is a complex disease in which metastasis to the bone is the main cause of death. Initial stages of metastasis are generally similar to those for most solid tumors; however, the mechan...
Bone metastases in prostate cancer

Prostate cancer (PCa) usually metastasizes to bone tissue before other sites, remaining confined to bone in almost 80% of men presenting with advanced disease. Lymph node metastases are detected radiologically in 20% of patients while lung and liver metastasis are relatively rare 1. Bony metastasis damages the skeleton mechanically, through compression of the vascular system and consequent ...
Bone metastasis occurs in up to 90% of advanced prostate cancer patients, metastatic prostate cancer is generally considered a non-curative condition which can impact quality of life. The tumor microenvironment, comprising diverse cellular and non-cellular elements, interacts with prostate cancer cells to affect tumor growth and bone metastasis .

Prostate Cancer Spread to Bones
Prostate cancer is one of the types of cancer that is most likely to spread, or metastasize, to bones . There are four main stages of prostate cancer , and stage 4 often involves bone metastases.
Clinically relevant bone metastases are a major cause of morbidity and mortality for prostate cancer patients. Distinct phenotypes are described: osteoblastic, the more common osteolytic and mixed. A molecular classification has been also proposed. Bone metastases start with the tropism of cancer cells to the bone through different multi-step tumor-host interactions, as described by the ...

Bone metastases of prostate cancer
Prostate cancer (PCa) is second only to lung cancer in terms of death among men worldwide. Advanced PCa frequently results in bone metastases, which occur in ~90% of patients and frequently result in severe skeleton‑related events. Currently, the treatment for this disease is limited to alleviating its clinical symptoms and cannot provide a complete cure. Therefore, the development of novel ...





